Palopegteriparatide Patent Expiration
Palopegteriparatide was first introduced by Ascendis Pharma Bone Diseases As
Palopegteriparatide Patents
Given below is the list of patents protecting Palopegteriparatide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Yorvipath | US11590207 | Dosage regimen for a controlled-release PTH compound | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11759504 | PTH compounds with low peak-to-trough ratios | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11857603 | PTH compounds with low peak-to-trough ratios | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11890326 | Controlled-release PTH compound | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11918628 | Controlled-release PTH compound | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US8906847 | Prodrug comprising a drug linker conjugate | Apr 30, 2031 | Ascendis Pharma Bone |
Palopegteriparatide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List